Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

A pilot study previously demonstrated that thrice-weekly, fractionated-dose intravenous rituximab (RTX) limits CD20 loss from chronic lymphocytic leukemia (CLL) B cells, thereby enhancing immunotherapeutic targeting. Here, we investigated the feasibility of giving 20 mg rituximab subcutaneously thri...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Aue, Georg, Lindorfer, Margaret A., Beum, Paul V., Pawluczkowycz, Andrew W., Vire, Berengere, Hughes, Thomas, Taylor, Ronald P., Wiestner, Adrian
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2010
Sujets:
Brief Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2817038/
https://ncbi.nlm.nih.gov/pubmed/19679883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.012484
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires